Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jun 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the role of certain immune cells called Myeloid Derived Suppressor Cells (MDSCs) in people with Systemic Lupus Erythematosus (SLE), a complex condition that can cause various health issues, including joint pain, skin problems, and kidney or nervous system issues. The researchers want to learn more about how these cells behave in SLE, especially during flare-ups, to better understand their effects on the immune system and explore new treatment options.

To participate in this study, you must be at least 18 years old and have active systemic lupus erythematosus, meaning your disease is currently affecting you. You will not be eligible if you have other active autoimmune diseases, infections, or cancer. While the study is not yet recruiting participants, those who join can expect to undergo tests that will help scientists learn more about MDSCs and their potential role in SLE treatment. Your participation could contribute to important discoveries that may help others living with this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Active systemic lupus erythematosus (SLEDAI \> or = 1)
• • Written informed consent
• Exclusion Criteria:
• • Chronic or acute infection
• • Other active auto-immune condition
• • Active cancer
• • Age below 18